View in EDS

Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern

Saved in:
Bibliographic Details
Title: Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
Authors: Yu-Chi Chou, Luke Tzu-Chi Liu, Charles Chen, Chia-En Lien, Jinyi Cheng, Yi-Jiun Lin, Meei-Yun Lin, Wei-Cheng Lian, Tsun-Yung Kuo
Source: Clin Infect Dis
Publisher Information: Oxford University Press (OUP), 2021.
Publication Year: 2021
Subject Terms: Major Articles and Commentaries, Adjuvants, Immunologic, Viral Envelope Proteins, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vaccines, Subunit, Animals, COVID-19, Humans, Antibodies, Viral, Antibodies, Neutralizing, Rats, 3. Good health
Description: Background Variants of concern (VoCs) have the potential to diminish the neutralizing capacity of antibodies elicited by vaccines. MVC-COV1901 is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine consisting of recombinant prefusion stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. We explored the effectiveness of MVC-COV1901 against the VoCs. Methods Serum samples were taken from rats and phase 1 clinical trial human subjects immunized with a low, medium, or high dose of MVC-COV1901. The neutralizing titers of serum antibodies were assayed with pseudoviruses coated with the SARS-CoV-2 spike protein of the wild-type (WT), D614G, Alpha, or Beta variants. Results Rats vaccinated twice with vaccine containing high doses of antigen retained high levels of neutralization activity against the Beta variant, albeit with a slight reduction compared to WT. After the third dose, neutralizing titers against the Beta variant were noticeably enhanced regardless of the amount of antigen used for immunization. In humans, vaccinated phase 1 subjects still showed appreciable neutralization abilities against the D614G, Alpha, and Beta variants, although neutralizing titers were significantly reduced against the Beta variant. Conclusions Two doses of MVC-COV1901 were able to elicit neutralizing antibodies against SARS-CoV-2 variants with an overall tendency of inducing higher immune response at a higher dose level. The neutralizing titers to the Beta variant in rats and humans were lower than those for WT and the Alpha variant. An additional third dose in rats was able to partially compensate for the reduction in neutralization against the Beta variant. We have demonstrated that immunization with MVC-COV1901 was effective against VoCs.
Document Type: Article
Other literature type
Language: English
ISSN: 1537-6591
1058-4838
DOI: 10.1093/cid/ciab711
Access URL: https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab711/41088464/ciab711.pdf
https://pubmed.ncbi.nlm.nih.gov/34739037
https://www.ncbi.nlm.nih.gov/pubmed/34739037
https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/zh/covidwho-1504298
https://europepmc.org/article/MED/34739037
https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab711/41088464/ciab711.pdf
https://pubmed.ncbi.nlm.nih.gov/34739037/
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Accession Number: edsair.doi.dedup.....33a55afdecf8dccaad8d6ee6f1fec2bc
Database: OpenAIRE
Description
Abstract:Background Variants of concern (VoCs) have the potential to diminish the neutralizing capacity of antibodies elicited by vaccines. MVC-COV1901 is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine consisting of recombinant prefusion stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. We explored the effectiveness of MVC-COV1901 against the VoCs. Methods Serum samples were taken from rats and phase 1 clinical trial human subjects immunized with a low, medium, or high dose of MVC-COV1901. The neutralizing titers of serum antibodies were assayed with pseudoviruses coated with the SARS-CoV-2 spike protein of the wild-type (WT), D614G, Alpha, or Beta variants. Results Rats vaccinated twice with vaccine containing high doses of antigen retained high levels of neutralization activity against the Beta variant, albeit with a slight reduction compared to WT. After the third dose, neutralizing titers against the Beta variant were noticeably enhanced regardless of the amount of antigen used for immunization. In humans, vaccinated phase 1 subjects still showed appreciable neutralization abilities against the D614G, Alpha, and Beta variants, although neutralizing titers were significantly reduced against the Beta variant. Conclusions Two doses of MVC-COV1901 were able to elicit neutralizing antibodies against SARS-CoV-2 variants with an overall tendency of inducing higher immune response at a higher dose level. The neutralizing titers to the Beta variant in rats and humans were lower than those for WT and the Alpha variant. An additional third dose in rats was able to partially compensate for the reduction in neutralization against the Beta variant. We have demonstrated that immunization with MVC-COV1901 was effective against VoCs.
ISSN:15376591
10584838
DOI:10.1093/cid/ciab711